Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis - a pilot trial.

Author: Berg-HansenP, BrochL, BunessA, Burum-AuensenE, FallangL-E, FarbuE, HolmK, HolmøyT, HovJ R, MidgardR, MyhrK-M, NyquistK, Storm-LarsenC, UelandT

Paper Details 
Original Abstract of the Article :
INTRODUCTION: Patients with multiple sclerosis may have a distinct gut microbiota profile. Delayed-release dimethyl fumarate is an orally administered drug for relapsing-remitting multiple sclerosis, which has been associated with gastrointestinal side-effects in some patients. OBJECTIVES: The purp...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859687/

データ提供:米国国立医学図書館(NLM)

Unveiling the Gut Microbiota's Role in Multiple Sclerosis Treatment

The gut microbiome, a complex ecosystem of bacteria and other microorganisms residing in our intestines, is increasingly recognized as a key player in various aspects of human health, including our immune system. This study delves into the intricate relationship between the gut microbiota and the effectiveness of dimethyl fumarate, a medication used to treat relapsing-remitting multiple sclerosis (MS). This research employed a pilot trial to investigate whether dimethyl fumarate alters the composition and diversity of gut bacteria, and if these changes are linked to gastrointestinal side effects.

Dimethyl Fumarate's Impact on the Gut Microbiome

The study observed a baseline difference in the gut microbiota of MS patients compared to healthy individuals. Interestingly, while dimethyl fumarate didn't significantly alter the overall composition of the gut microbiota, the study noted a trend towards normalization of the abundance of butyrate-producing bacteria in the treated group. Butyrate is a short-chain fatty acid known for its beneficial effects on gut health and overall well-being.

Navigating the Gut-Brain Connection

This study provides valuable insights into the complex interplay between the gut microbiota and MS treatment. It highlights the potential role of dimethyl fumarate in influencing the gut microbiome, and emphasizes the importance of further research to understand the precise mechanisms involved. As we continue to unravel the secrets of the gut-brain connection, we gain a deeper understanding of how our gut bacteria can influence both our physical and mental health.

Dr.Camel's Conclusion

The gut microbiome is a hidden oasis in the desert of human health, influencing our immune system and overall well-being. This study provides valuable insights into how a medication for MS might interact with this intricate ecosystem. While the results suggest a potential role for dimethyl fumarate in modulating the gut microbiota, further research is needed to fully understand its effects. This journey of discovery is like a camel navigating the desert, with each step bringing us closer to a deeper understanding of the intricate connections within our bodies!

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-04-11
Further Info :

Pubmed ID

31798939

DOI: Digital Object Identifier

PMC6859687

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.